| Title: |
Low-dose aspirin and progression of age-related hearing loss:a secondary analysis of the ASPREE Randomized Clinical Trial |
| Authors: |
Clark, David P. Q.; Zhou, Zhen; Hussain, Sultana M.; Tran, Cammie; Britt, Carlene; Storey, Elsdon; Lowthian, Judy A.; Shah, Raj C.; Dillon, Harvey; Wolfe, Rory; Woods, Robyn L.; Rance, Gary; McNeil, John J. |
| Source: |
Clark, D P Q, Zhou, Z, Hussain, S M, Tran, C, Britt, C, Storey, E, Lowthian, J A, Shah, R C, Dillon, H, Wolfe, R, Woods, R L, Rance, G & McNeil, J J 2024, 'Low-dose aspirin and progression of age-related hearing loss : a secondary analysis of the ASPREE Randomized Clinical Trial', JAMA Network Open, vol. 7, no. 7, e2424373, pp. 1-12. https://doi.org/10.1001/jamanetworkopen.2024.24373 |
| Publication Year: |
2024 |
| Subject Terms: |
humans; aspirin/therapeutic use; male; female; aged; disease progression; presbycusis/drug therapy; Australia; anti-Inflammatory Agents; Non-Steroidal/administration & dosage; 80 and over; hearing loss/prevention & control; double-Blind Method; speech perception/drug effects |
| Description: |
IMPORTANCE: Age-related hearing loss is common in an aging population, affecting communication and contributing to a worsened quality of life. It occurs as a result of cochlear degeneration and may be further exacerbated by inflammation and microvascular changes, as observed in animal models. OBJECTIVE: To compare the effect of daily low-dose aspirin vs placebo on the progression of age-related hearing loss in healthy older adults. DESIGN, SETTING, AND PARTICIPANTS: A prespecified secondary analysis was conducted of the Aspirin in Reducing Events in the Elderly (ASPREE) randomized clinical trial. Participants were 279 healthy community-dwelling individuals living in Australia who were aged 70 years or older and free of overt cardiovascular diseases, dementia, and life-limiting illnesses. Participants were recruited between January 1, 2010, and December 31, 2014, and followed up over 3 years. Statistical analysis was completed from June to December 2023. INTERVENTION: A 100-mg daily dose of enteric-coated aspirin or matching placebo. MAIN OUTCOMES AND MEASURES: Hearing measures were air conduction audiometry and binaural speech perception in noise. Assessments were conducted at baseline, 18 months, and 3 years. The change from baseline hearing measures were analyzed using an intention to treat approach. Aspirin and placebo were compared using mixed linear regression models adjusting for age, sex, diabetes, and smoking. RESULTS: Of 279 participants, 154 (55%) were male, and the median age at baseline was 73.1 years (IQR, 71.5-76.2 years). A total of 98 of 138 participants (71%) in the aspirin group and 94 of 141 participants (67%) in the placebo group reported experiencing hearing loss at baseline. Compared with placebo, aspirin did not affect the changes in mean (SD) 4-frequency average hearing threshold from baseline to year 3 (aspirin: baseline, 27.8 [13.3] dB; year 3, 30.7 [13.7] dB; difference, 3.3 [3.9] dB; placebo: baseline, 27.5 [12.6] dB; year 3, 30.9 [13.8] dB; difference, 3.0 [4.8] dB; P = .55) nor any ... |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| ISSN: |
2574-3805 |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/39052288; info:eu-repo/semantics/altIdentifier/wos/001278029700012; info:eu-repo/semantics/altIdentifier/pissn/2574-3805; info:eu-repo/semantics/altIdentifier/eissn/2574-3805 |
| DOI: |
10.1001/jamanetworkopen.2024.24373 |
| Availability: |
https://researchers.mq.edu.au/en/publications/6ee49e41-a700-4ccd-923a-b755c1465395; https://doi.org/10.1001/jamanetworkopen.2024.24373; https://research-management.mq.edu.au/ws/files/356006507/355996635.pdf; https://www.scopus.com/pages/publications/85199659398 |
| Rights: |
info:eu-repo/semantics/openAccess ; http://creativecommons.org/licenses/by/4.0/ |
| Accession Number: |
edsbas.2947B963 |
| Database: |
BASE |